This is a working overview of adipose tissue, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-12 and is reviewed periodically as new material appears.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
The shape of the light curve of these supernovae at intermediate to late-times corresponds to the decay via electron capture of 56Ni to cobalt-56 and ultimately to iron-56. Nickel-59 is a long-lived cosmogenic radionuclide; half-life 76,000 years. 59Ni has found many applications in isotope geology. 59Ni has been used to date the terrestrial age of meteorites and to determine abundances of extraterrestrial dust in ice and sediment. Nickel-78, with a half-life of 110 milliseconds, is believed an important isotope in supernova nucleosynthesis of elements heavier than iron. 48Ni, discovered in 1999, is the most proton-rich heavy element isotope known. With 28 protons and 20 neutrons, 48Ni is "doubly magic", as is 78Ni with 28 protons and 50 neutrons. Both are therefore unusually stable for nuclei with so large a proton–neutron imbalance. Nickel-63 is a contaminant found in the support structure of nuclear reactors. It is produced through neutron capture by nickel-62. Small amounts have also been found near nuclear weapon test sites in the South Pacific.
The Hong Kong Rugby Football Union was founded in 1953. Rugby is long established, partly as a result of its being a British colony. Hong Kong Sevens is held annually in Hong Kong and is considered the premier tournament on the World Rugby Sevens Series competition. Hong Kong national rugby union team is ranked 23rd in the world with a peak rating of 21st (2018–2022). Hong Kong is one of the best teams in Asia and has finished first place in the Asia Rugby Championship in 2018, 2019, 2022, 2023, 2024, and 2025. They qualified for the 2027 Rugby World Cup for the first time by winning the 2025 Asia Rugby Championship. The Hong Kong national rugby sevens team is widely regarded as the best rugby sevens team in Asia and a regular participant in the Rugby World Cup Sevens. Hong Kong has won the Asian Sevens Series a record 8 times and the Asian Games 2 times.
τν is the spectral optical depth in frequency, and τλ is the spectral optical depth in wavelength. Although absorbance is properly unitless, it is sometimes reported in "absorbance units", or AU. Many people, including scientific researchers, wrongly state the results from absorbance measurement experiments in terms of these made-up units.
== Health concerns == Health experts are concerned about the increased consumption and popularity of functional beverages. Most functional beverages are sweetened, and consumption of sweetened beverages is associated with higher levels of obesity and heart disease. Most of these drinks contain significant amounts of sugars and hence calories, which would add to discretionary and total caloric intake. As such, these ingredients pose health risks because of what they contain (sugar and caffeine) or what they replace in the diet (vitamin and mineral-rich foods).
Sources: en.wikipedia.org
=== Effects on longitudinal bone growth === Cilostazol has been investigated in preclinical models as a stimulator of endochondral bone growth. PDE3 is expressed in proliferating chondrocytes of the growth plate, and that Pde3b-knockout mice show enlargement of the tibia and other long bones. In embryonic mouse metatarsal explant cultures, cilostazol at 10 μM increased longitudinal outgrowth over four days, expanding the round and columnar chondrocyte zones and increasing alcian-blue-stained extracellular matrix; the PDE3 inhibitors milrinone, anagrelide and olprinone produced comparable effects, while inhibitors selective for PDE2 or PDE10 did not. When three-week-old C57BL/6 mice received daily intraperitoneal injections of cilostazol at 10 mg/kg for four weeks, naso-anal body length was significantly greater than in vehicle-treated controls, and a similar growth-promoting effect was observed in Fgfr3-transgenic mice, a model of achondroplasia. Mechanistically, the authors proposed that PDE3 inhibition raises intracellular cyclic GMP in growth-plate chondrocytes — cilostazol-treated bones showed an approximately 1.7-fold increase in cGMP — activating protein kinase G, which phosphorylates plasma-membrane potassium channels. The resulting membrane hyperpolarisation is thought to enhance the driving force for TRPM7-mediated Ca²⁺ entry and thereby stimulate cartilage matrix synthesis, converging on the C-type natriuretic peptide (CNP) signalling axis targeted clinically by vosoritide.
== Chemerin-derived peptides == A particular synthetic chemerin-derived peptide, termed C15, was developed at Oxford University. It showed anti-inflammatory activities. Intraperitoneal administration of C15 (0.32 ng/kg) to mice before zymosan challenge conferred significant protection against zymosan-induced peritonitis, suppressing neutrophil (63%) and monocyte (62%) recruitment with a concomitant reduction in proinflammatory mediator expression. C15 was found to promote phagocytosis and efferocytosis in peritoneal macrophages at picomolar concentrations. C15 enhanced macrophage clearance of microbial particles and apoptotic cells by factor of 360% in vitro. Another chemerin-derived peptide, termed C-20, was developed at the Shenzhen Institute of Advanced Technology. Administration C-20 uncovered its high affinity binding to chemerin receptors CMKLR1 and GPR1, mimicking chemerin’s activity but with lower potency. C-20 triggered receptor internalization, promoted chemotaxis, and mildly suppressed hormone production (testosterone and progesterone), suggesting its potential as a tool to study chemerin-related signaling pathways.
Skin conditions resulting from errors in metabolism are caused by enzymatic defects that lead to an accumulation or deficiency of various cellular components, including, but not limited to, amino acids, carbohydrates, and lipids.
Sources: en.wikipedia.org
=== Selenoproteins === Selenocysteine has a lower reduction potential than cysteine. These properties make it very suitable in proteins that are involved in antioxidant activity. Although it is found in the three domains of life, it is not universal in all organisms. Unlike other amino acids present in biological proteins, selenocysteine is not coded for directly in the genetic code. Instead, it is encoded in a special way by a UGA codon, which is normally the "opal" stop codon. Such a mechanism is called translational recoding and its efficiency depends on the selenoprotein being synthesized and on translation initiation factors. When cells are grown in the absence of selenium, translation of selenoproteins terminates at the UGA codon, resulting in a truncated, nonfunctional enzyme. The UGA codon is made to encode selenocysteine by the presence of a selenocysteine insertion sequence (SECIS) in the mRNA. The SECIS element is defined by characteristic nucleotide sequences and secondary structure base-pairing patterns. In bacteria, the SECIS element is typically located immediately following the UGA codon within the reading frame for the selenoprotein. In Archaea and in eukaryotes, the SECIS element is in the 3′ untranslated region (3′ UTR) of the mRNA and can direct multiple UGA codons to encode selenocysteine residues. As of 2021, 136 human proteins (in 37 families) are known to contain selenocysteine (selenoproteins).
In April 2002, Yosri Fouda of Al Jazeera met al-Qaeda member Khalid Sheikh Mohammed and bin al-Shibh, who were in hiding, and they admitted to him their involvement in the attacks. Mohammed had been an organizer and financier of al-Qaeda's 1993 bombing of the World Trade Center, and he was the uncle of Ramzi Yousef, the lead bomber in that attack. Mohammed and Yousef planned another terrorist attack, the Bojinka plot, for January 1995. Despite its failure, and Yousef's imprisonment by the U.S. afterwards, the plot would influence the later September 11 attacks. The 2004 9/11 Commission Report determined that the animosity that Mohammed, the principal architect of 9/11, felt towards the U.S. had stemmed from his "violent disagreement with U.S. foreign policy favoring Israel."
== U == Ultrasound attenuation spectroscopy UPS – UV-photoelectron spectroscopy USANS – Ultra small-angle neutron scattering USAXS – Ultra small-angle X-ray scattering UT – Ultrasonic testing UV-Vis – Ultraviolet–visible spectroscopy
== Financials == The company has reported total income of Rs.2073.3345 crores during the Financial Year ended March 31, 2023 as compared to Rs.1181.7454 crores during the Financial Year ended March 31, 2022. The company has posted net profit of Rs.120.78 crores for the Financial Year ended March 31, 2023 as against net profit of Rs.49.6759 crores for the Financial Year ended March 31, 2022.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.